BioWorld

Aug. 30, 2006

SGX Stock Plummets After Troxatyl Fails In Phase II/III

Shares in SGX Pharmaceuticals Inc. suffered mightily on Tuesday following a Phase II/III study stoppage. (BioWorld Today) Read More

ViroPharma Stock Boosted By Early Data For HCV-796

Valeritas' SPAC Deal Gets $140M For Insulin Therapy

New Firm ApopLogic Taking Aim At Cell Death Pathways

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 11, 2025.

AI-generated illustration of heart and metabolic impact

Deep Apple signs big Novo deal for cardiometabolic small molecules

BioWorld

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...

DNA double helix under a magnifying glass

23andme genetic privacy concerns garner Congressional scrutiny

BioWorld MedTech

The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...